Jae H Kang1, Cheng Peng1, Jinnie J Rhee2, Maryam S Farvid3, Walter C Willett3,4, Frank B Hu1,3, Bernard A Rosner1,5, Rulla Tamimi1,3, A Heather Eliassen1,3. 1. Channing Division of Network Medicine, Department of Medicine, Brigham & Women's Hospital, Boston, MA, USA. 2. Division of Nephrology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA. 3. Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA, USA. 4. Department of Nutrition, Harvard TH Chan School of Public Health, Boston, MA, USA. 5. Department of Biostatistics, Harvard TH Chan School of Public Health, Boston, MA, USA.
Abstract
BACKGROUND: Hyperinsulinemia and higher insulin-like growth factors may increase breast cancer risk. We evaluated a diabetes risk reduction diet (DRRD) and breast cancer risk. OBJECTIVES: We prospectively evaluated the association between adherence to a DRRD and the incidence of breast cancer. METHODS: We followed 88,739 women from the Nurses' Health Study (NHS; 1980-2016) and 93,915 women from the NHSII (1991-2017). Incident breast cancer cases (n = 11,943) were confirmed with medical records, and subtypes were determined by tissue microarray data and pathology reports. Information on diet and breast cancer risk factors was repeatedly ascertained in follow-up questionnaires. A DRRD score was derived with 9 factors: lower glycemic index of diet; lower intakes of trans fat, sugar-sweetened beverages/fruit juices, and red/processed meat; higher intakes of cereal fiber, coffee, nuts, and whole fruits; and a higher ratio of polyunsaturated to saturated fat (score range: 9-45). Multivariable-adjusted hazard ratios (MVHRs) and 95% CIs were calculated with Cox proportional hazards models. RESULTS: Being in the highest compared with the lowest DRRD adherence quintile was associated with a modestly lower breast cancer risk (MVHRQ5vsQ1: 0.89; 95% CI: 0.84, 0.95; P-trend = 0.0002); this was attenuated after adjusting for weight change since age 18 y (MVHRQ5vsQ1: 0.92; 95% CI: 0.87, 0.98; P-trend = 0.01). The inverse association was strongest among women with current BMI < 25 kg/m2 (MVHRQ5vsQ1: 0.89; 95% CI: 0.81, 0.98; P-trend = 0.004; P-interaction = 0.04). Among tumor molecular subtypes, the strongest inverse association was observed with basal-type tumors (MVHRQ5vsQ1: 0.67; 95% CI: 0.45, 1.01; P-trend = 0.04). CONCLUSIONS: Greater DRRD-adherence was associated with lower breast cancer risk, likely mediated by less weight gain with a DRRD; however, independently of weight change, DRRD-adherence was modestly associated with lower breast cancer risk, particularly among lean women.
BACKGROUND:Hyperinsulinemia and higher insulin-like growth factors may increase breast cancer risk. We evaluated a diabetes risk reduction diet (DRRD) and breast cancer risk. OBJECTIVES: We prospectively evaluated the association between adherence to a DRRD and the incidence of breast cancer. METHODS: We followed 88,739 women from the Nurses' Health Study (NHS; 1980-2016) and 93,915 women from the NHSII (1991-2017). Incident breast cancer cases (n = 11,943) were confirmed with medical records, and subtypes were determined by tissue microarray data and pathology reports. Information on diet and breast cancer risk factors was repeatedly ascertained in follow-up questionnaires. A DRRD score was derived with 9 factors: lower glycemic index of diet; lower intakes of trans fat, sugar-sweetened beverages/fruit juices, and red/processed meat; higher intakes of cereal fiber, coffee, nuts, and whole fruits; and a higher ratio of polyunsaturated to saturated fat (score range: 9-45). Multivariable-adjusted hazard ratios (MVHRs) and 95% CIs were calculated with Cox proportional hazards models. RESULTS: Being in the highest compared with the lowest DRRD adherence quintile was associated with a modestly lower breast cancer risk (MVHRQ5vsQ1: 0.89; 95% CI: 0.84, 0.95; P-trend = 0.0002); this was attenuated after adjusting for weight change since age 18 y (MVHRQ5vsQ1: 0.92; 95% CI: 0.87, 0.98; P-trend = 0.01). The inverse association was strongest among women with current BMI < 25 kg/m2 (MVHRQ5vsQ1: 0.89; 95% CI: 0.81, 0.98; P-trend = 0.004; P-interaction = 0.04). Among tumor molecular subtypes, the strongest inverse association was observed with basal-type tumors (MVHRQ5vsQ1: 0.67; 95% CI: 0.45, 1.01; P-trend = 0.04). CONCLUSIONS: Greater DRRD-adherence was associated with lower breast cancer risk, likely mediated by less weight gain with a DRRD; however, independently of weight change, DRRD-adherence was modestly associated with lower breast cancer risk, particularly among lean women.
Authors: Changzheng Yuan; Donna Spiegelman; Eric B Rimm; Bernard A Rosner; Meir J Stampfer; Junaidah B Barnett; Jorge E Chavarro; Amy F Subar; Laura K Sampson; Walter C Willett Journal: Am J Epidemiol Date: 2017-04-01 Impact factor: 4.897
Authors: Vladimir N Anisimov; Peter A Egormin; Tatiana S Piskunova; Irina G Popovich; Margarita L Tyndyk; Maria N Yurova; Mark A Zabezhinski; Ivan V Anikin; Arseniy S Karkach; Alexey A Romanyukha Journal: Cell Cycle Date: 2010-01-22 Impact factor: 4.534
Authors: Edward Giovannucci; David M Harlan; Michael C Archer; Richard M Bergenstal; Susan M Gapstur; Laurel A Habel; Michael Pollak; Judith G Regensteiner; Douglas Yee Journal: Diabetes Care Date: 2010-07 Impact factor: 19.112
Authors: Lluis Fajas; Rebecca L Landsberg; Yolande Huss-Garcia; Claude Sardet; Jacqueline A Lees; Johan Auwerx Journal: Dev Cell Date: 2002-07 Impact factor: 12.270
Authors: Andrea Romanos-Nanclares; Walter C Willett; Bernard A Rosner; Laura C Collins; Frank B Hu; Estefania Toledo; A Heather Eliassen Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-07-21 Impact factor: 4.254
Authors: Tengteng Wang; Maryam S Farvid; Jae H Kang; Michelle D Holmes; Bernard A Rosner; Rulla M Tamimi; Walter C Willett; A Heather Eliassen Journal: Cancer Res Date: 2021-06-09 Impact factor: 12.701